Inovio Pharmaceuticals

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative.

Find a broker to begin trading INO now

Company Name Inovio Pharmaceuticals
Market/Symbol NASDAQ: INO
Recent Price
Market Cap $418.97M
Avg. Daily Vol. (3m) 1,257,746
Price/Book N/A
Price/Cash Flow N/A
As of Jan. 23, 2018
*Source: QuoteMedia

Begin trading INO

 Find Broker



Inovio Pharmaceuticals Latest News

Ask the CEO

Meet The Board of Directors

Avtar Dhillon

Chairman of the Board, Inovio Pharmaceuticals

Simon X. Benito

Former Senior Vice President, Vaccine Division, Merck

Angel Cabrera

President, George Mason University

Morton Collins

General Partner, Battelle Ventures

J. Joseph Kim

President & Chief Executive Officer, Inovio Pharmaceuticals

Adel Mahmoud

Former President, Merck Vaccines and Chief Medical Advisor, Vaccines & Infectious Diseases, Merck Professor, Dept. of Molecular Biology, Princeton University

Meet The Management Team

J. Joseph Kim

President, Chief Executive Officer, Director

Peter Kies

Chief Financial Officer

Niranjan Y. Sardesai

Chief Operating Officer

Mark L. Bagarazzi

Chief Medical Officer

Stephen Kemmerrer

Vice President, Engineering Operations

Thomas Kim

Vice President, Legal and Corporate Secretary

Historical SEC Filings

Date Form Title
Jan 08, 2018 8-K 8-K - Current report
Jan 02, 2018 8-K 8-K - Current report
Dec 06, 2017 8-K 8-K - Current report
Nov 08, 2017 10-Q 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 02, 2017 8-K 8-K - Current report
Aug 08, 2017 10-Q 10-Q - Quarterly report [Sections 13 or 15(d)]
Jul 20, 2017 8-K 8-K - Current report
Jul 20, 2017 424B5 424B5 - Prospectus [Rule 424(b)(5)]
Jul 18, 2017 8-K 8-K - Current report
Jul 18, 2017 424B5 424B5 - Prospectus [Rule 424(b)(5)]

Receive INO Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market